Fortress Biotech 9.375% Series A Preferred Stock
FBIOP
3 hedge funds and large institutions have $5.87M invested in Fortress Biotech 9.375% Series A Preferred Stock in 2022 Q1 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 2 reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 3 → 3 (0)
0.72% less ownership
Funds ownership: 7.86% → 7.14% (-0.72%)
16% less capital invested
Capital invested by funds: $6.98M → $5.87M (-$1.11M)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Shikiar Asset Management
New York
|
-$581K |
| 2 |
UIC
Uniplan Investment Counsel
Milwaukee,
Wisconsin
|
-$25.3K |
FBIOP Hedge Fund Activity: Q1 2022 in Review
3 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Fortress Biotech 9.375% Series A Preferred Stock (FBIOP) for Q1 2022, worth a combined $5.87M — down 16% from $6.98M a quarter earlier.
Fund positioning in FBIOP was balanced in Q1 2022: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 2 trimmed.
The largest seller was Shikiar Asset Management, cutting an estimated $581K.
- 3 institutional investors held Fortress Biotech 9.375% Series A Preferred Stock (FBIOP) as of Q1 2022, unchanged from Q4 2021.
- Funds reported $5.87M of Fortress Biotech 9.375% Series A Preferred Stock stock for Q1 2022, down 16% quarter-over-quarter.
- 0 funds opened new Fortress Biotech 9.375% Series A Preferred Stock positions in Q1 2022 and 0 closed out.
- The largest Fortress Biotech 9.375% Series A Preferred Stock seller in Q1 2022 was Shikiar Asset Management, an estimated $581K sold.
Based on aggregated 13F filings for Q1 2022.